User:Mohamed Moubarak: Difference between revisions
No edit summary |
|||
| (10 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
Mohamed Moubarak, M.D [mailto:dr.mohamed.moubarak@gmail.com] | [[Image:M_Moubarak.jpg|right|250px|Mohamed Moubarak, M.D.]] | ||
'''Mohamed Moubarak, M.D.''', Research fellow at PERFUSE Study Group, Beth Israel Deaconess Medical Center, Harvard Medical School. | |||
'''Contact:''' mmoubarak@wikidoc.org[mailto:mmoubarak@wikidoc.org]; or at his G mail address: dr.mohamed.moubarak@gmail.com [mailto:dr.mohamed.moubarak@gmail.com] | |||
==Education== | |||
*United States Medical License Examination | |||
**ECFMG Certificate 2012 | |||
*M.B.Ch.B Cairo University School of Medicine- Egypt 2000-2008 | |||
==Membership and Honorary/Professional Societies== | |||
Egyptian Society of Cardiology. 2010 – Present | |||
EAMTAR online medical society. Member, clinical skills advisory 2009 - Present | |||
==Research Experience== | |||
*Ain Shams University Hospital (July2012-Jan2013) Egypt | |||
**Research Assistant, Dr. Sara H. Farahat, M.D | |||
A Double Blinded comparative study between the effects and the side effects of 400 & 600 Micrograms of Misoprostol given rectally for the prevention of postpartum hemorrhage. After delivery of the infants and within 5 min of clamping and cutting of the cord, women are given 3 tablets either 3 Misotac or 2 Misotac & 1 Placebo rectally (each Misotac tab. Is 200 Microgram of Misoprostol, produced by sigma pharmaceutical industries, SAE, Egypt), the women monitored for postpartum hemorrhage occurrence for 6 hours | |||
*Academy of Scientific Research and Technology (March2008- October2008) Egypt | |||
**Medical Patent examiner, Mr. Mohamed Tarek Hussein- The Head of The Academy | |||
International classification for patents on inventions in the field of medicine. Technical researches in the field of patents on inventions of medicine according to local and international database. Technical reports of the initial technical examination, during this period, i had the online DL-101 certificate of general course of intellectual property from WIPO Academy, Geneva, Switzerland | |||
Latest revision as of 02:26, 31 October 2013
Mohamed Moubarak, M.D., Research fellow at PERFUSE Study Group, Beth Israel Deaconess Medical Center, Harvard Medical School.
Contact: mmoubarak@wikidoc.org[1]; or at his G mail address: dr.mohamed.moubarak@gmail.com [2]
Education
- United States Medical License Examination
- ECFMG Certificate 2012
- M.B.Ch.B Cairo University School of Medicine- Egypt 2000-2008
Membership and Honorary/Professional Societies
Egyptian Society of Cardiology. 2010 – Present
EAMTAR online medical society. Member, clinical skills advisory 2009 - Present
Research Experience
- Ain Shams University Hospital (July2012-Jan2013) Egypt
- Research Assistant, Dr. Sara H. Farahat, M.D
A Double Blinded comparative study between the effects and the side effects of 400 & 600 Micrograms of Misoprostol given rectally for the prevention of postpartum hemorrhage. After delivery of the infants and within 5 min of clamping and cutting of the cord, women are given 3 tablets either 3 Misotac or 2 Misotac & 1 Placebo rectally (each Misotac tab. Is 200 Microgram of Misoprostol, produced by sigma pharmaceutical industries, SAE, Egypt), the women monitored for postpartum hemorrhage occurrence for 6 hours
- Academy of Scientific Research and Technology (March2008- October2008) Egypt
- Medical Patent examiner, Mr. Mohamed Tarek Hussein- The Head of The Academy
International classification for patents on inventions in the field of medicine. Technical researches in the field of patents on inventions of medicine according to local and international database. Technical reports of the initial technical examination, during this period, i had the online DL-101 certificate of general course of intellectual property from WIPO Academy, Geneva, Switzerland